# Risk of subsequent gliomas and meningiomas among 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study

**Authors:** Emma J. Heymer, Michael M. Hawkins, David L. Winter, Jop C. Teepen, Ceren Sunguc, Cécile M. Ronckers, Rodrigue S. Allodji, Daniela Alessi, Elaine Sugden, Fabiën N. Belle, Francesca Bagnasco, Julianne Byrne, Edit Bárdi, Stanislaw Garwicz, Desiree Grabow, Momcilo Jankovic, Peter Kaatsch, Melanie Kaiser, Gisela Michel, Christina Schindera, Nadia Haddy, Neige Journy, Maja Česen Mazić, Roderick Skinner, Judith L. Kok, Maria W. Gunnes, Thomas Wiebe, Carlotta Sacerdote, Milena M. Maule, Monica Terenziani, Zsuzsanna Jakab, Jeanette F. Winther, Päivi M. Lähteenmäki, Lorna Zadravec Zaletel, Riccardo Haupt, Claudia E. Kuehni, Leontien C. Kremer, Florent de Vathaire, Lars Hjorth, Raoul C. Reulen

PMC · DOI: 10.1038/s41416-024-02577-y · British Journal of Cancer · 2024-01-19

## TL;DR

Childhood cancer survivors, especially those treated with cranial radiotherapy, face a long-term risk of developing gliomas and meningiomas into adulthood.

## Contribution

This study provides the largest cohort analysis of subsequent glioma and meningioma risks in childhood cancer survivors beyond age 40.

## Key findings

- CNS tumor survivors had a 16.2-fold increased risk of subsequent glioma.
- Cumulative incidence of meningioma doubled between ages 40 and 60 for CNS tumor survivors treated with cranial radiotherapy.
- Leukaemia survivors had a 10.2-fold increased glioma risk after age 40 following cranial radiotherapy.

## Abstract

Childhood cancer survivors are at risk of subsequent gliomas and meningiomas, but the risks beyond age 40 years are uncertain. We quantified these risks in the largest ever cohort.

Using data from 69,460 5-year childhood cancer survivors (diagnosed 1940–2008), across Europe, standardized incidence ratios (SIRs) and cumulative incidence were calculated.

In total, 279 glioma and 761 meningioma were identified. CNS tumour (SIR: 16.2, 95% CI: 13.7, 19.2) and leukaemia (SIR: 11.2, 95% CI: 8.8, 14.2) survivors were at greatest risk of glioma. The SIR for CNS tumour survivors was still 4.3-fold after age 50 (95% CI: 1.9, 9.6), and for leukaemia survivors still 10.2-fold after age 40 (95% CI: 4.9, 21.4). Following cranial radiotherapy (CRT), the cumulative incidence of a glioma in CNS tumour survivors was 2.7%, 3.7% and 5.0% by ages 40, 50 and 60, respectively, whilst for leukaemia this was 1.2% and 1.7% by ages 40 and 50. The cumulative incidence of a meningioma after CRT in CNS tumour survivors doubled from 5.9% to 12.5% between ages 40 and 60, and in leukaemia survivors increased from 5.8% to 10.2% between ages 40 and 50.

Clinicians following up survivors should be aware that the substantial risks of meningioma and glioma following CRT are sustained beyond age 40 and be vigilant for symptoms.

## Linked entities

- **Diseases:** CNS tumour (MONDO:0006130), leukaemia (MONDO:0004355)

## Full-text entities

- **Diseases:** cancer (MESH:D009369), meningioma (MESH:D008579), leukaemia (MESH:D015458), glioma (MESH:D005910), CNS tumour (MESH:D016543)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC10951281/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC10951281/full.md

## References

36 references — full list in the complete paper: https://tomesphere.com/paper/PMC10951281/full.md

---
Source: https://tomesphere.com/paper/PMC10951281